Defining and Treating Cystic Fibrosis Liver Disease: Some Things Old and Some Things New

Affiliations

¹ Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada. Electronic address: gary.galante@albertahealthservices.ca.

Free article

Editorial

Gary J Galante. J Cyst Fibros. 2022 Mar.

Free article

. 2022 Mar;21(2):199-201.

doi: 10.1016/j.jcf.2022.03.004.

¹ Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada. Electronic address: gary.galante@albertahealthservices.ca.

No abstract available

Comment on

Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study.
Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, Alghisi F, Kashirskaya N, Kondratyeva E, Corti F, Padoan R, Asherova I, Evans H, de Monestrol I, Strandvik B, Lindblad A; CF UDCA study group. Colombo C, et al. J Cyst Fibros. 2022 Mar;21(2):220-226. doi: 10.1016/j.jcf.2021.03.014. Epub 2021 Apr 2. J Cyst Fibros. 2022. PMID: 33814323
Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
Lowry S, Mogayzel PJ, Oshima K, Karnsakul W. Lowry S, et al. J Cyst Fibros. 2022 Mar;21(2):e99-e101. doi: 10.1016/j.jcf.2021.07.001. Epub 2021 Jul 16. J Cyst Fibros. 2022. PMID: 34275759 No abstract available.
The impact of liver disease on mortality in cystic fibrosis-A systematic review.
Sasame A, Stokes D, Bourke B, Connolly L, Fitzpatrick E, Rowland M. Sasame A, et al. J Cyst Fibros. 2022 Mar;21(2):202-211. doi: 10.1016/j.jcf.2021.07.014. Epub 2021 Aug 8. J Cyst Fibros. 2022. PMID: 34380590
Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
McKinzie CJ, Doligalski CT, Lobritto SJ, Coakley RD, Gower WA. McKinzie CJ, et al. J Cyst Fibros. 2022 Mar;21(2):227-229. doi: 10.1016/j.jcf.2021.07.017. Epub 2021 Aug 9. J Cyst Fibros. 2022. PMID: 34384711 No abstract available.